19 / 25
RECORD-1
(N=416)
4
CheckMate-025
(N=821)
5
METEOR
(N=658)
6,7
HOPE 205
(N=153)
8,9
ALTERNATIVA
Everolimus
Nivolumab
Cabozantinib
Lenvatinib +
everolimus
COMPARADOR
Placebo
Everolimus
(mTORi)
Everolimus
(mTORi)
Everolimus
(mTORi)
MEDIANA SLP
HR(95% CI)
4.9 vs 1.9
0.33 (0.25–0.43)
p<0.001
4.6 vs 4.4
0.88 (0.75–1.03)
p<0.11
7.4 vs 3.8
0.58 (0.45–0.75)
p<0.001
12.8 vs 5.6
0.45 (0.27–0.79)
p=0.029
MEDIANA SG
HR(95% CI)
14.8 vs 14.4
0.87 (0.65–1.15)
p=0.162
25.0 vs 19.6
0.73 (0.57–0.93)
p=0.002
21.4 vs 16.5
0.66 (0.53–0.83)
p=0.00026
25.5 vs 15.4
0.68 (0.41–1.14)
p=0.12
RESPUESTAS
OBJETIVAS (%)
1.8 vs 0
NA
25 vs 5
p<0.001
17 vs 3
p<0.0001
35 vs 0
p<0.0001
EFICACIA TERAPÉUTICA EN 2ª y SUBSIGUIENTES LÍNEAS
4. Motzer RJ,
et al. Cancer
2010;116:4256–65;
5. Motzer RJ,
et al. NEJM
2015;373:1803–13; 6. Choueiri TK,
et al. NEJM
2015;373:1814–23; 7. Choueiri TK, et al
. Lancet Oncol
2016;17:917–27
; 8.
Motzer RJ,
et al
.
Lancet Oncol
2015;16:1473–82 8; 9. Motzer RJ,
et al. Lancet Oncol
2016;17:e4–5
.